ESPR Mid-Q1 '19 Update

ESPR entered into a major partnership agreement with Daichi Sankyo Europe to commercialize bempadoic acid (BA), its oral drug for lowering LDL-C for patients who are on maximum statins, in Europe. The market did not react favorably to the deal likely because Daichi is not a top 3 worldwide cardio company, but we think the deal is a good one for ESPR and further validates the value of BA. You can see more details on our Catalyst Calendar entry at


*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Big Movers™ is a trademark of Amp Biotech Research, LLC

©2021 by Biopharm IQ. Website by Awaken Studio.